Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of metastatic uveal melanoma
Economic burden and healthcare resource utilization
4 evidence topics · 6 sources
All-cause healthcare costs and resource use in U.S. commercial, Medicare, and Medicaid claims
Healthcare costs by treatment type and adverse event-related costs in U.S. commercial and Medicare claims
| Treatment group (Commercial and Medicare patients) | Mean all-cause healthcare costs per patient per month (2025 US$) | Mean adverse event-related costs per patient per month (2025 US$) | Adverse event-related costs as a percentage of all-cause costs |
|---|---|---|---|
| All patients (n=423) | “$28,859” | “$2,607” | “9.0%” |
| Chemotherapy (n=77) | “$30,682” | “$3,944” | “12.9%” |
| Checkpoint inhibitors (n=145) | “$36,056” | “$4,158” | “11.5%” |
| Tebentafusp (n=39) | “$93,805” | “$6,746” | “7.2%” |
| Liver directed therapy (n=80) | “$35,509” | “$3,078” | “8.7%” |